US FDA finds control lapses at Moderna manufacturing plant 



Reuters exclusively reported that U.S. drug regulators in September found quality control lapses at Moderna’s (MRNA.O) main factory including with equipment used to manufacture drug substance for its COVID-19 vaccine. 

Market Impact

Moderna in September said it was in talks with its partners that fill vials and syringes with its COVID vaccine globally to downsize production and bring more manufacturing in-house as demand has waned. The vaccine maker said it expects additional capacity from its new mRNA manufacturing facilities in the UK, Canada and Australia when completed in 2025.

Article Tags

Topics of Interest: Health

Type: Reuters Best

Sectors: Government & Public ServicesPharmaceuticals & Healthcare

Regions: Americas

Countries: United States

Win Types: Exclusivity

Story Types: Exclusive / Scoop

Media Types: Text

Customer Impact: Significant National Story


Source link

Related articles

Free at home Covid tests available starting Monday

[ad_1] COVID-19 home test kits are pictured in a store window during the coronavirus disease (COVID-19) pandemic in the Manhattan borough of New York City, New York, U.S., January 19, 2022. Carlo Allegri | Reuters The Biden administration on Monday said it is offering another round of free at-home Covid tests to U.S. households ahead […]

GE Healthcare (GEHC) stock finally gets some respect after Q4 earnings

[ad_1] Business at GE Healthcare Technologies capped off 2023 on a strong note despite ongoing concerns about China. That coupled with management’s upbeat view of this year propelled shares up more than 13% to over $83 each at session highs. That was their highest level since July 2023. The Club stock closed just under $82. […]

Leave a Reply

Your email address will not be published. Required fields are marked *